Thiazolidinedione use in elderly patients with type 2 diabetes: With and without heart failure

Pharmacoepidemiology and Drug Safety

Volumn 20, Issue 4, 2011, Pages 344-350

  Seong, Jong Mi ^a   Choi, Nam Kyong ^a,b   Jung, Sun Young ^c   Chang, Yoosoo ^a,d   Kim, Ye Jee ^a   Lee, Joongyub ^a,e   Park, Byung Joo ^a,b,e  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University   (South Korea)

^c National Evidence Based Healthcare Collaborating Agency   (South Korea)

^d Sungkyunkwan University   (South Korea)

^e Seoul National University Hospital   (South Korea)

Author keywords

Aged: 65+ years; Drug utilization; Heart failure; Thiazolidinediones; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; INSULIN; MEGLITINIDE; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA;

AGED; ARTICLE; COMBINATION CHEMOTHERAPY; DRUG UTILIZATION; FEMALE; GERIATRIC PATIENT; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; FEMALE; HEART FAILURE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; PHYSICIAN'S PRACTICE PATTERNS; REPUBLIC OF KOREA; THIAZOLIDINEDIONES;

EID: 79953050027     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2112     Document Type: Article

References (23)

1. Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 2004; 27: 1879-1884.
2. Mehta RH, Ruane TJ, McCargar PA, Eagle KA, Stalhandske EJ. The treatment of elderly diabetic patients with acute myocardial infarction: insight from Michigan's Cooperative Cardiovascular Project. Arch Intern Med 2000; 160: 1301-1306.
3. Gottdiener JS, Arnold AM, Aurigemma GP, et al. Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol 2000; 35: 1628-1637.
4. Kannel WB. Vital epidemiologic clues in heart failure. J Clin Epidemiol 2000; 53: 229-235.
5. Rich MW. Epidemiology, pathophysiology, and etiology of congestive heart failure in older adults. J Am Geriatr Soc 1997; 45: 968-974.
6. Senni M, Tribouilloy CM, Rodeheffer RJ, et al. Congestive heart failure in the community: trends in incidence and survival in a 10-year period. Arch Intern Med 1999; 159: 29-34.
7. Croft JB, Giles WH, Pollard RA, Keenan NL, Casper ML, Anda RF. Heart failure survival among older adults in the United States: a poor prognosis for an emerging epidemic in the Medicare population. Arch Intern Med 1999; 159: 505-510.
8. Dries DL, Sweitzer NK, Drazner MH, Stevenson LW, Gersh BJ. Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction. J Am Coll Cardiol 2001; 38: 421-428.
9. Parulkar AA, Pendergrass ML, Granda-Ayala R, Lee TR, Fonseca VA. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 2001; 134: 61-71 [erratum in: Ann Intern Med 2001; 135: 307].
10. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106: 679-684.
11. Product information: Avandia [rosiglitazone]. GlaxoSmithKline Korea, 2008.
12. Product information: Actos [pioglitazone]. Lilly Korea, 2008.
13. Masoudi FA, Wang Y, Inzucchi SE, et al. Metformin and Thiazolidinedione use in Medicare patients with heart failure. JAMA 2003; 290: 81-85.
14. FDA News. Manufacturers of some diabetes drugs to strengthen warning on heart failure risk, 2007; (accessed 29 June 2010).
15. FDA News. FDA significantly restricts access to the diabetes drug Avandia. (accessed 10 December 2010).
16. EMA News. European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim. (accessed 10 December 2010).
17. Choi NK, Hahn S, Park BJ. Increase in mortality rate following coprescription of cisapride and contraindicated drugs. Ann Pharmacother 2007; 41: 667-673.
18. Hunt SA, Abraham WT, Chin MH, et al. American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005; 112: e154-235.
19. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2008; 31: 173-175.
20. Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care 2006; 29: 554-559.
21. Tsai YW, Wen YW, Huang WF, et al. Pharmaceutical penetration of new drug and pharmaceutical market structure in Taiwan: hospital-level prescription of thiazolidinediones for diabetes. Eur J Health Econ 2010; 11: 279-290.
22. Korean Diabetes Association, Health Insurance Review & Assessment Service: Report of Task Force Team for Basic Statistics Study: Diabetes in Korea 2007.
23. Park BJ, Sung JH, Park KD, Seo SW, Kim SW. Report of the evaluation for validity of discharged diagnoses in Korean Health Insurance database. Seoul: Seoul National University 2003; 19-52.